Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | FABP6 | P51161 | 1/20 | 0.43 |
| ▸ | RB1 | P06400 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7161614 | 1.00 | GRIN2B (0.49) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL7521305 | 1.00 | GRIN2B (0.49) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL22674521 | 0.77 | GRIN2B (0.50) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL23948575 | 0.77 | GRIN2B (0.50) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL10039743 | 0.77 | GRIN2B (0.50) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL6269523 | 0.77 | JAK2 (0.50) | ACHEKMT2A | |
| SCHEMBL7723868 | 0.76 | GRIN2B (0.66) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL571765 | 0.75 | GRIN2B (0.71) | GRIN2BBCHEACHEBACE1MEN1 | |
| SCHEMBL14699811 | 0.75 | ACHE (0.49) | GRIN2BFYNBCHEACHEBACE1 | |
| SCHEMBL13896045 | 0.75 | GRIN2B (0.51) | GRIN2BFYNBCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | claimed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | GRIN2B 53/4885FYN 686/4885BCHE 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.